Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Placebo-controlled, Randomized, Parallel Group, Dose-finding Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With FSAD and/or HSDD

Next Previous
Trial Profile

A Placebo-controlled, Randomized, Parallel Group, Dose-finding Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With FSAD and/or HSDD

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bremelanotide (Primary)
  • Indications Female sexual dysfunction
  • Focus Therapeutic Use
  • Sponsors Palatin Technologies

Most Recent Events

  • 30 Apr 2018 Results assessing age and weight subgroup analysis from 2 phase 3 studies (RECONNECT) and one phase 2 study (profile: 201617) presented at the 66th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists
  • 01 May 2014 Responder analysis published in the Obstetrics and Gynecology.
  • 01 Mar 2013 Results were presented at the International Society for the Study of Women's Sexual Health (ISSWSH) conference in March 2013.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top